NextCell Pharma AB (STO:NXTCL)
Sweden · Delayed Price · Currency is SEK 1.088
+0.008 (0.74%)
Sep 2, 2026, 5:08 PM CET
NextCell Pharma AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 |
Cash & Equivalents | 21.09 | 26.03 | 38.72 | 46.79 | 50.03 | 97.12 |
Cash & Short-Term Investments | 21.09 | 26.03 | 38.72 | 46.79 | 50.03 | 97.12 |
Cash Growth | -19.93% | -32.77% | -17.24% | -6.47% | -48.49% | -30.22% |
Accounts Receivable | 4.67 | 3.06 | 3 | 1.67 | 2.35 | 1.78 |
Other Receivables | 16.03 | 2.4 | 1.98 | 1.45 | 1.24 | 0.93 |
Receivables | 20.7 | 5.47 | 4.98 | 3.12 | 3.58 | 2.71 |
Inventory | 0.33 | 0.33 | 0.55 | 0.55 | 0.79 | 0.77 |
Prepaid Expenses | - | 9.57 | 10.15 | 10.17 | 12.87 | 6.16 |
Other Current Assets | - | - | - | 0.05 | 0 | - |
Total Current Assets | 42.11 | 41.4 | 54.4 | 60.67 | 67.27 | 106.75 |
Property, Plant & Equipment | 13.52 | 14.27 | 14.33 | 12.66 | 13.55 | 9.9 |
Long-Term Investments | 8.27 | 7.2 | 6.87 | 6.92 | 6.87 | 6.87 |
Other Long-Term Assets | - | 1.05 | 1.14 | 1.03 | 1.13 | 1.13 |
Total Assets | 63.9 | 63.92 | 76.73 | 81.29 | 88.83 | 124.66 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 |
Accounts Payable | 5.43 | 3.34 | 2.69 | 6.16 | 0.89 | 1.92 |
Accrued Expenses | - | 3.38 | 2.25 | 2.49 | 7.65 | 4.16 |
Current Unearned Revenue | - | - | - | 0.25 | 0.2 | - |
Other Current Liabilities | 5.91 | 1.31 | 0.49 | 0.98 | 1.35 | 0.85 |
Total Current Liabilities | 11.34 | 8.03 | 5.43 | 9.87 | 10.08 | 6.93 |
Long-Term Unearned Revenue | - | 5.29 | 4.92 | 3.82 | 3.02 | 2.18 |
Other Long-Term Liabilities | 5.49 | 0 | -0 | -0 | -0 | - |
Total Liabilities | 16.83 | 13.32 | 10.34 | 13.69 | 13.1 | 9.12 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 |
Common Stock | 25.91 | 22.84 | 22.84 | 14.98 | 7.05 | 7.05 |
Additional Paid-In Capital | 263.87 | 248.41 | 248.41 | 222.33 | 196.43 | 196.43 |
Retained Earnings | -242.71 | -220.64 | -204.85 | -169.71 | -127.75 | -87.94 |
Shareholders' Equity | 47.07 | 50.6 | 66.39 | 67.6 | 75.73 | 115.54 |
Total Liabilities & Equity | 63.9 | 63.92 | 76.73 | 81.29 | 88.83 | 124.66 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 |
Net Cash (Debt) | 21.09 | 26.03 | 38.72 | 46.79 | 50.03 | 97.12 |
Net Cash Growth | -19.93% | -32.77% | -17.24% | -6.47% | -48.49% | -30.22% |
Net Cash Per Share | 0.17 | - | 0.51 | 1.15 | 1.46 | 2.82 |
Filing Date Shares Outstanding | 126.39 | 111.39 | 111.39 | 73.09 | 34.38 | 34.38 |
Total Common Shares Outstanding | 126.39 | 111.39 | 111.39 | 73.09 | 34.38 | 34.38 |
Working Capital | 30.77 | 33.37 | 48.97 | 50.8 | 57.19 | 99.82 |
Book Value Per Share | 0.37 | 0.45 | 0.60 | 0.92 | 2.20 | 3.36 |
Tangible Book Value | 47.07 | 50.6 | 66.39 | 67.6 | 75.73 | 115.54 |
Tangible Book Value Per Share | 0.37 | 0.45 | 0.60 | 0.92 | 2.20 | 3.36 |
Machinery | - | - | - | 16.04 | 5.22 | 5.15 |
Construction In Progress | - | - | - | - | 11.59 | 7.56 |